PROKIDNEY CORP
PROKNASDAQTrading Snapshot
- Day Range
- $1.62 – $1.65
- 52-Week Range
- $1.30 – $3.48
- Volume
- $2.81B
- Avg Volume
- $2.11B
- Shares Outstanding
- 336.3M
- Next Earnings
- Dec 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $893,000
- Last Q Revenue
- $150,000
- P/E Ratio
- -2.9
- P/S Ratio
- 670.0x
- EPS (TTM)
- $-0.46
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +9.7%
Why Investors Own PROK
- ✓High-growth profile — revenue up +18.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PROKIDNEY CORP
PROK
StockOtter · stockotter.spaceAbout PROKIDNEY CORP
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Critical Analysis: Pyxis Oncology (NASDAQ:PYXS) vs. ProKidney (NASDAQ:PROK)
ProKidney (NASDAQ: PROK - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the stren
20 stocks likely to lose money even if the bull market continues
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)
ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therapy, rilparencel. Phase 2 data for rilparencel is weak, with confounding factors and no robust evidence of efficacy; Phase
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.